These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32255214)

  • 1. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
    Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
    An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice.
    Song H; Hu Z; Zhang S; Yang L; Liu Y; Wang T
    Dermatol Ther; 2022 Nov; 35(11):e15821. PubMed ID: 36114601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
    Yousefian F; Yadlapati S; Browning JC
    J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 8. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study.
    Asawanonda P; Klahan SO
    Photomed Laser Surg; 2010 Oct; 28(5):679-84. PubMed ID: 20961233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of low-dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: A pilot study.
    Fang WC; Chiu SH; Lin SY; Huang SM; Lan CE
    Photodermatol Photoimmunol Photomed; 2021 Jul; 37(4):345-347. PubMed ID: 33512041
    [No Abstract]   [Full Text] [Related]  

  • 11. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K; Phan S; Shumack S; Gupta M
    J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
    Kang C
    Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study.
    Garza-Mayers AC; Paquette GM; Harris JE; Wiss K
    J Am Acad Dermatol; 2023 Jul; 89(1):135-136. PubMed ID: 36796727
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of tretinoin 0.05% cream to prevent hyperpigmentation during narrowband UV-B phototherapy in patients with facial vitiligo: a randomized clinical trial.
    Ju HJ; Kim SH; Lee JH; Kim GM; Bae JM
    J Dermatolog Treat; 2022 May; 33(3):1738-1741. PubMed ID: 32869680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy.
    Dayal S; Sahu P; Gupta N
    Pediatr Dermatol; 2016 Nov; 33(6):646-651. PubMed ID: 27699846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical and Maintenance Treatments for Vitiligo.
    Passeron T
    Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a preceding fractional carbon dioxide laser on the outcome of combined local narrowband ultraviolet B and topical steroids in patients with vitiligo in difficult-to-treat areas.
    Vachiramon V; Chaiyabutr C; Rattanaumpawan P; Kanokrungsee S
    Lasers Surg Med; 2016 Feb; 48(2):197-202. PubMed ID: 26175036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.